B. Riley analyst Anderson Schock lowered the firm’s price target on OptimizeRx (OPRX) to $11 from $28 and keeps a Buy rating on the shares. The firm views the company’s Q4 results as strong, but says the quarter was overshadowed by the lowered fiscal 2026 revenue outlook. Riley cites reduced revenue visibility, the lowered 2026 growth outlook, and falling peer multiples for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $18 from $32 at Roth Capital
- OptimizeRx price target lowered to $17 from $21 at Stifel
- OptimizeRx price target lowered to $10 from $17 at Stephens
- OptimizeRx: Strong Q4 Execution, Temporary Headwinds, and Raised Profitability Guidance Support Buy Rating
- OptimizeRx Authorizes $10 Million Share Repurchase Program